Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype (Q44395024)

2 December 2017

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype (English)

1 reference

2 December 2017

1 reference

Pedro Dorado

3

0 references

author name string

Roland Berecz

1

1 reference

2 December 2017

Alfredo de la Rubia

2

1 reference

2 December 2017

Pedro Fernández-Salguero

4

1 reference

2 December 2017

Marja-Liisa Dahl

5

1 reference

2 December 2017

Adrián LLerena

6

1 reference

2 December 2017

28 March 2003

1 reference

European Journal of Clinical Pharmacology

2 December 2017

1 reference

2 December 2017

59

1 reference

2 December 2017

45-50

1 reference

2 December 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-003-0576-4

2 December 2017

0 references

cites work

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Effects of smoking on fluphenazine clearance in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0576-4

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

21 January 2018

1 reference

12 December 2020

Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes

1 reference

12 December 2020

Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current

1 reference

12 December 2020

Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR

1 reference

12 December 2020

Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.

1 reference

12 December 2020

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents

1 reference

12 December 2020

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data

1 reference

12 December 2020

Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline

1 reference

12 December 2020

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

1 reference

12 December 2020

Smokers need higher doses of neuroleptic drugs

1 reference

12 December 2020

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart

1 reference

12 December 2020

Thioridazine interferences with imipramine metabolism and measurement

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Inhibition of trazodone metabolism by thioridazine in humans

1 reference

12 December 2020

Debrisoquine oxidation phenotype in psychiatric patients.

1 reference

12 December 2020

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1 reference

12 December 2020

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

1 reference

12 December 2020

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

12 December 2020

Debrisoquin oxidation polymorphism in a Spanish population

1 reference

12 December 2020

Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine.

1 reference

12 December 2020

Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat

1 reference

12 December 2020

10.1007/S00228-003-0576-4

Identifiers

DOI

1 reference

2 December 2017

1 reference